Building An AAV8 Platform, Together: Lessons From A Collaborative Development Journey

By Paul Cashen, Katy McLaughlin, and Franziska Bollmann, Sartorius

As gene therapy programs accelerate toward clinical and commercial readiness, the need for scalable, GMP-compliant AAV8 manufacturing platforms has never been greater. This white paper presents a collaborative effort between Matica Biotechnology and Sartorius to develop a modular, end-to-end AAV8 production process that delivers reproducibility, flexibility, and speed. From upstream transfection optimization to downstream purification and analytics, the platform integrates single-use technologies, design of experiments, and digital tools to streamline development and tech transfer. Key outcomes include consistent titers, effective capsid separation, and strong impurity clearance—all demonstrated at 50 L scale.

Whether you're building your first vector process or refining an existing one, gain practical insights into scalable viral vector manufacturing.